Congress Moves to Cement Trump Psychedelics Research Executive Order
Bipartisan House bill seeks to make Trump's psychedelics research directive permanent law, potentially accelerating clinical trials and market access.
Four House representatives from both parties introduced legislation this week to transform President Trump's executive order on psychedelic medicine research into permanent federal law. The Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Act, led by Reps. Morgan Luttrell (R-TX), Lou Correa (D-CA), Jack Bergman (R-MI), and Michael McCaul (R-TX), represents a rare moment of bipartisan cooperation on alternative medicine policy.
The legislative push comes as psychedelics companies face mounting pressure to demonstrate clinical efficacy and navigate complex regulatory pathways. Trump's executive order aimed to reduce bureaucratic barriers for researchers studying compounds like psilocybin and MDMA, which have shown promise in treating PTSD, depression, and other mental health conditions. Converting this directive into statutory law would provide more durable regulatory clarity that cannot be easily reversed by future administrations.
Psychedelics stocks have experienced extreme volatility as investors grapple with regulatory uncertainty and mixed clinical trial results. Companies like Compass Pathways and ATAI Life Sciences have seen their valuations fluctuate dramatically based on FDA guidance and trial outcomes. Permanent legislative backing for streamlined research protocols could provide the stability these companies need to attract sustained institutional investment.
The cannabis industry watches psychedelics developments closely, as many operators view these compounds as a natural expansion opportunity. Several major cannabis companies have already established psychedelics divisions or partnerships, anticipating eventual market convergence. The regulatory framework established for psychedelics research could also influence how federal agencies approach cannabis studies, particularly as both substances face similar scheduling challenges under the Controlled Substances Act.
While the bill's passage remains uncertain given congressional priorities, the bipartisan sponsorship suggests growing recognition of psychedelics' therapeutic potential. Success would mark a significant shift in federal drug policy and could accelerate the timeline for commercial psychedelics markets, potentially creating new revenue streams for companies positioned at the intersection of cannabis and psychedelics research.